Document is current
Any future updates will be listed below
-
Authors
,
Hägg-Holmberg, Stefanie
Dahlström, Emma H.
Forsblom, Carol M.
Harjutsalo, Valma
Liebkind, Ron
Putaala, Jukka
Tatlisumak, Turgut
Groop, Per-Henrik
Thorn, Lena M.
-
Funding
Funding for this research was provided by:
Wilhelm och Else Stockmanns Stiftelse
The Medical Society of Finland
Helsinki University Central Hospital Research Funds and the Academy of Finland
Medicinska Understödsföreningen Liv och Hälsa
Signe ja Ane Gyllenbergin Säätiö
Waldemar von Frenckell Foundation
The Diabetes Research Foundation
Novo Nordisk Foundation
Biomedicum Helsinki-säätiö
Diabetes Wellness Finland
Stiftelsen Dorothea Olivia, Karl Walter och Jarl Walter Perkléns Minne
Nylands Nation
Folkhälsan Research Foundation
- License Information
-
More Information
Article History
Received: 16 March 2019
Accepted: 25 June 2019
First Online: 9 July 2019
Ethics approval and consent to participate
: The local ethics committee of each center approved the study protocol, and the study was carried out in accordance with the Declaration of Helsinki. Each participant signed a written informed consent.
: Not applicable.
: TT. has served on scientific advisory boards for Bayer, Boehringer Ingelheim, Lumosa Pharm, and Pfizer; T.T. has received speaker´s bureau from University of Donau (Austria). P.-H.G. has received research grants from Eli Lilly and Roche. He is an advisory board member for AbbVie, Astra Zeneca, Boehringer-Ingelheim, Cebix, Eli Lilly, Janssen, MSD, Medscape, Novartis, and Sanofi. He has also received speaker honorariums from Astra Zeneca, Boehringer-Ingelheim, Eli Lilly, Elo Water, Genzyme, MSD, Novartis, Novo Nordisk, and Sanofi. Other authors have no competing interests relevant to this paper.
